Addex Therapeutics Ltd
ADXNNASDAQHealthcare● Active
$5.86
+$0.00(+0.00%)
Market Cap$4220665
P/E Ratio—
52W High$12.05
52W Low$5.41
Addex Therapeutics Ltd (ADXN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADXN · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.03M | $0.40M | $1.61M | $1.42M | $2.92M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.03M | $0.40M | $1.61M | $1.42M | $2.92M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.19M | $0.44M | $0.94M | $7.88M | $9.01M |
| G&A Expenses | $1.89M | $1.68M | $2.03M | $3.26M | $7.75M |
| Total Operating Expenses | $2.84M | $3.16M | $3.86M | $11.96M | $18.42M |
| Operating Income | ($2.81M) | ($2.76M) | ($2.24M) | ($10.54M) | ($15.51M) |
| Operating Margin %(computed) | — | -681.82% | -139.06% | -741.04% | -531.70% |
| Interest Income | $0.00M | $0.01M | $0.06M | $0.03M | $0.01M |
| Interest Expense | $0.00M | $0.00M | $0.02M | $0.05M | $0.06M |
| Income Before Tax | ($6.84M) | ($4.91M) | ($2.50M) | ($10.80M) | ($15.35M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($6.73M) | $7.06M | ($10.56M) | ($20.80M) | ($15.35M) |
| Net Margin %(computed) | — | — | -654.47% | — | -526.42% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.88 | $8.40 | $-16.80 | $-55.20 | $-54.00 |
| Wtd Avg Shares | 0.94M | 0.82M | 0.62M | 0.38M | 0.28M |
| EBITDA | ($6.83M) | ($4.65M) | ($2.19M) | ($10.45M) | ($14.94M) |
| EBITDA Margin %(computed) | — | — | -135.80% | -734.86% | -512.34% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CHF · M
Explore more Addex Therapeutics Ltd data
About Addex Therapeutics Ltd (ADXN) Income Statement
Addex Therapeutics Ltd (ADXN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ADXN reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.01B) — a net profit margin of -22448.44%.
Frequently asked questions
ADXN · 4 questionsAddex Therapeutics Ltd (ADXN) reported revenue of $0.00B for 2025, down 92.6% year-over-year.
ADXN revenueADXN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09